Beam Therapeutics

Contributing Author

Recent Articles by Beam Therapeutics

Jun-18	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration BEAM +5.11% GlobeNewswire
May-18	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference BEAM GlobeNewswire
May-13	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference BEAM GlobeNewswire
May-12	Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 BEAM GlobeNewswire
May-07	Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates BEAM GlobeNewswire
Apr-01	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine BEAM GlobeNewswire
Mar-25	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development BEAM GlobeNewswire
Feb-24	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) BEAM +13.98% GlobeNewswire
Feb-24	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street BEAM +13.98% GlobeNewswire
Feb-23	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program BEAM GlobeNewswire
Jan-11	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition BEAM GlobeNewswire
Dec-18	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference BEAM GlobeNewswire
Dec-06	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting BEAM GlobeNewswire
Nov-12	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference BEAM GlobeNewswire
Nov-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates BEAM -6.23% GlobeNewswire
Nov-03	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting BEAM GlobeNewswire
Aug-25	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences BEAM GlobeNewswire
Aug-14	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease BEAM GlobeNewswire
Aug-05	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
Jun-13	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
Jun-03	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease BEAM GlobeNewswire
May-29	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-14	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
May-13	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference BEAM GlobeNewswire
May-12	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-06	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights BEAM -19.32% GlobeNewswire

Beam Therapeutics

Recent Articles by Beam Therapeutics

Upgrade your Finviz experience